<< Back to Results
ACOSOG Z1031 - A Randomized Phase III Trial Comparing 16 to 18 Weeks of Neoadjuvant Exemestane (25mg daily), Letrozole (2.5 mg), or Anastrozole (1mg) in Postmenopausal Women with Clinical Stage II and III Estrogen Receptor Positive Breast Cancer.
Clinical Trial Categories
- The Rosenfeld Cancer Center at 215-481-2402
- The Rosenfeld Cancer Center